Diligence memo · auto-generated · as of July 3, 2026
Metagenomi Technologies, LLC
Metagenomi Technologies, LLC looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Metagenomi Technologies, LLC operates in Biotechnology, based in Emeryville.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Metagenomi Technologies, LLC has raised $345M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $175M on 2022-01-21.
Most recent recorded round closed around 2022-12-20.
Valuation (modeled)modeled
Provath models Metagenomi Technologies, LLC at approximately $1.7B (range $434M–$2.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.87× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era. Within the normal band (87% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 3.5 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.